OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Director exercised or converted 4,665 GILD derivative securities | OQRO

Home
Insider trades
Gilead Sciences
Director exercised or converted 4,665 GILD derivative securities

Insider trades

Insider trade

Director exercised or converted 4,665 GILD derivative securities

Traded Aug 20, 2026 · Filed Aug 21, 2026

GILGilead SciencesGILD

4,665
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 20, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 21, 2026

DirectorOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001771814-26-000005

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Aug 21, 2026, 11:22 PM UTC

Added to OQRO

Oct 2, 2026, 12:27 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

GILEAD SCIENCES, INC.

Issuer CIK

882095

Ticker

GILD

Reporting person

Jeffrey Bluestone

Relationship

Director

Security

Non-qualified Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

Aug 20, 2026

Transaction code

Shares / units

4,665

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

Ownership form

Direct

Amendment

Footnotes from the filing

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.
25% of the shares subject to the option vested on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option are fully vested.

Around the same time

Andrew D Dickinson (Chief Financial Officer) sold ~$436K of Gilead Sciences

Scheduled in advanceFiled 3w ago

Johanna Mercier (Chief Comm & Corp Aff Officer) sold ~$230K of Gilead Sciences

Scheduled in advanceFiled 3w ago

Johanna Mercier (Chief Comm & Corp Aff Officer) sold ~$116K of Gilead Sciences

Scheduled in advanceFiled 3w ago